G1 Therapeutics falls as cancer treatment fails to meet late-stage study goal

G1 Therapeutics

12/02/2024 22:09

** Shares of drug maker G1 Therapeutics  GTHX.O  fall 36.6%
to $2.86 in extended trade
    ** Co says it will continue a late-stage trial on its
experimental combination treatment using its approved lung
cancer therapy Cosela with chemotherapy drugs gemcitabine and
carboplatin for a type of breast cancer
    ** GTHX had previously said it will stop the study if it met
its interim overall survival (OS) criteria; OS determines the
duration of patient survival from the time of treatment
initiation
    ** Co says final analysis evaluating OS is expected in Q3
2024 
    ** Stock fell 43.8% in 2023

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))